These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 43476)

  • 1. Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity.
    Nowycky MC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Nov; 309(3):247-54. PubMed ID: 43476
    [No Abstract]   [Full Text] [Related]  

  • 2. An investigation of the relationship between the dopaminergic and electroencephalographic effects of gamma-butyrolactone.
    Snead OC
    Neuropharmacology; 1982 Jun; 21(6):539-43. PubMed ID: 7110537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic neurons: reversal of effects elicited by gamma-butyrolactone by stimulation of the nigro-neostriatal pathway.
    Murrin LC; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Oct; 295(1):15-20. PubMed ID: 12482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse.
    Gianutsos G; Moore KE
    J Pharmacol Exp Ther; 1978 Dec; 207(3):859-69. PubMed ID: 731436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for down-regulation of GABA receptors following long-term gamma-butyrolactone.
    Gianutsos G; Suzdak PD
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Nov; 328(1):62-8. PubMed ID: 6096730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic inhibition of nigrostriatal dopamine release in the mouse: lack of cross tolerance between apomorphine, GBL and CGS 10746B.
    Wood PL; Altar CA; Kim HS
    Life Sci; 1988; 42(16):1503-6. PubMed ID: 3352463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine.
    Gianutsos G; Thornburg JE; Moore KE
    Psychopharmacology (Berl); 1976 Nov; 50(3):225-9. PubMed ID: 826966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-butyrolactone sleep: A 24-hour rhythm paralleling normal sleep in the rat and CNS amine changes.
    Speciale SG; Friedman AH
    Pharmacol Biochem Behav; 1975; 3(5):761-4. PubMed ID: 1208618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered activation of tyrosine hydroxylation by gamma-butyrolactone following chronic ethanol treatment.
    Liljequist S
    Drug Alcohol Depend; 1979; 4(3-4):261-3. PubMed ID: 43241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. gamma-Butyrolactone effects on behavior induced by dopamine agonists.
    Ellinwood EH; Gonzalez AE; Dougherty GG
    Biol Psychiatry; 1983 Sep; 18(9):1023-32. PubMed ID: 6685535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of gamma-butyrolactone on locomotor activity in the rat.
    Davies JA
    Psychopharmacology (Berl); 1978 Dec; 60(1):67-72. PubMed ID: 104348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?
    Argiolas A; Fadda F; Melis MR; Marcou M; Porceddu ML; Gessa GL
    Eur J Pharmacol; 1982 Nov; 85(1):23-7. PubMed ID: 6818043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chloral hydrate, gamma-butyrolactone, and equithesin on the efflux of dopamine and 5-hydroxytryptamine metabolites into cerebroventricular perfusates of rats.
    Nielsen JA; Moore KE
    J Neurochem; 1982 Jul; 39(1):235-8. PubMed ID: 6177832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of beta(4-chlorphenyl)GABA, gamma-hydroxybutyrolactone, and apomorphine on central dopamine neurons.
    Fuxe K; Agnati L; Everitt BJ; Hökfelt T; Ljungdahl A; Perez de la Mora M
    Adv Biochem Psychopharmacol; 1977; 16():489-94. PubMed ID: 883553
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
    Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic-like effects of the l-isomer of fenfluramine on striatal dopamine release in freely moving rats.
    Bettini E; Ceci A; Spinelli R; Samanin R
    Biochem Pharmacol; 1987 Jul; 36(14):2387-91. PubMed ID: 2886127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol and clozapine increase intraneuronal dopamine metabolism, but not gamma-butyrolactone-resistant dopamine release.
    Chrapusta SJ; Karoum F; Egan MF; Wyatt RJ
    Eur J Pharmacol; 1993 Mar; 233(1):135-42. PubMed ID: 8472742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma-butyrolactone.
    Dyck LE; Kazakoff CW
    J Neurosci Res; 1982; 8(1):57-65. PubMed ID: 7175978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supersensitivity of dopamine-autoreceptors. The effect of gammabutyrolactone in long-term haloperidol treated rats.
    Stock G; Steinbrenner J; Kummer P
    J Neural Transm; 1980; 47(2):145-51. PubMed ID: 7373289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of voluntary ethanol consumption in rats by gamma-butyrolactone.
    Fadda F; Argiolas A; Melis MR; De Montis G; Gessa GL
    Life Sci; 1983 Mar; 32(13):1471-7. PubMed ID: 6339856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.